Ionis Pharmaceuticals EVP O’Neil sells $937k in IONS stock

Patrick R. O’Neil, Executive Vice President, CLO & General Counsel at Ionis Pharmaceuticals Inc (NASDAQ:IONS), sold 13,441 shares of common stock on October 6, 2025, according to a recent SEC Filing. The sales were executed at weighted average prices ranging from $69.2651 to $69.8872, resulting in a total transaction value of approximately $937,337.

On the same day, O’Neil also exercised options to acquire 10,200 shares of Ionis Pharmaceuticals stock at a price of $52.87 per share, for a total value of $539,274. The timing is notable as the stock has shown remarkable strength, with InvestingPro data revealing a 174% surge over the past six months. For comprehensive insider trading analysis and 12 additional ProTips, investors can access the detailed Pro Research Report available on InvestingPro.

The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 2, 2025.

In other recent news, Ionis Pharmaceuticals has been the focus of multiple analyst updates and strategic announcements. The company recently held its Innovation Day, where it shared positive Phase 3 results for its drug olezarsen and provided updates on its pipeline progress. These developments have led Oppenheimer to raise its price target for Ionis to $90, maintaining an Outperform rating. Similarly, JPMorgan upgraded the stock to Overweight, increasing its price target from $49 to $80, citing successful Phase III data in Alexander Disease and other promising updates.

Stifel also increased its price target for Ionis from $43 to $67, maintaining a Hold rating, influenced by the performance of competitor treatments in the TTR market. Furthermore, Ionis outlined its growth strategy, which includes plans for four product launches by 2026, with two partner-led launches expected by the end of 2027. The company has already achieved two independent product launches in less than nine months. These strategic moves underscore Ionis Pharmaceuticals’ ongoing efforts to expand its market presence and development pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.